Fecal microbiota therapy: Ready for prime time?

Infection Control and Hospital Epidemiology

Volumn 35, Issue 1, 2014, Pages 28-30

  Rao, Krishna ^a   Young, Vincent B ^a   Aronoff, David M ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIDAXOMICIN; RIFAXIMIN; VANCOMYCIN;

CLOSTRIDIUM DIFFICILE INFECTION; DISEASE TRANSMISSION; DONOR; FECAL MICROBIOTA TRANSPLANTATION; FECES MICROFLORA; HUMAN; INCIDENCE; MATHEMATICAL MODEL; NOTE; PROPHYLAXIS; RECURRENT INFECTION; RISK FACTOR; SIMULATION; TRANSPLANTATION; TREATMENT OUTCOME;

BIOLOGICAL THERAPY; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; HUMANS; INTESTINES; MODELS, BIOLOGICAL;

EID: 84890404081     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/674395     Document Type: Note

References (19)

1. Hurley BW, Nguyen CC. The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea. Arch InternMed 2002;162(19):2177-2184.
2. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature 2012;486(7402): 222-227.
3. Figueroa I, Johnson S, Sambol SP, Goldstein EJC, Citron DM, Gerding DN. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin Infect Dis 2012;55(suppl 2):S104-S109.
4. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002;97(7):1769-1775.
5. Garey KW, Ghantoji SS, Shah DN, et al. A randomized, doubleblind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother 2011;66(12): 2850-2855.
6. Johnson S, Gerding DN. Fidaxomicin "chaser" regimen following vancomycin for patients with multiple C. difficile recurrences. Clin Infect Dis 2012;309-310.
7. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011;53(10):994-1002.
8. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013;368(5):407-415.
9. Lofgren ET, Moehring RW, Anderson DJ, Weber DJ, Fefferman NH. A mathematical model to evaluate the routine use of fecal microbiota transplantation to prevent incident and recurrent Clostridium difficile infection. Infect Control Hosp Epidemiol 2013;35:18-27 (in this issue).
10. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008;197(3):435-438.
11. Young VB, Schmidt TM. Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J Clin Microbiol 2004;42(3):1203-1206.
12. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366(9491):1079-1084.
13. Rao K, Micic D, Chenoweth E, et al. Poor functional status as a risk factor for severe Clostridium difficile infection in hospitalized older adults. J Am Geriatr Soc 2013;61(10):1738-1742.
14. Barbut F, Petit JC. Epidemiology of Clostridium difficile-associated infections. Clin Microbiol Infect 2001;7(8):405-410.
15. Welfare MR, Lalayiannis LC, Martin KE, Corbett S, Marshall B, Sarma JB. Co-morbidities as predictors of mortality in Clostridium difficile infection and derivation of the ARC predictive score. J Hosp Infect 2011;79(4):359-363.
16. Besselink MGH, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 371(9613):651-659.
17. De Leon LM, Watson JB, Kelly CR. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 2013;11(8): 1036-1038.
18. Sekirov I, Russell SL, Antunes LCM, Finlay BB. Gut microbiota in health and disease. Physiol Rev 2010;90(3):859-904.
19. Garrett WS, Lord GM, Punit S, et al. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 2007;131(1):33-45.